Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma's Well-Intentioned 'Improvements' To ICSRs Causing Problems In EudraVigilance

Executive Summary

EU marketing authorization holders are unknowingly duplicating individual case safety reports in the revamped EudraVigilance database, a senior regulator warns.

You may also be interested in...



EU Regulator's Enthusiasm for Revamped Pharmacovigilance Database Tempered By Industry Concerns

Following the launch of the revamped EudraVigilance database last November, a senior EU regulator believes these are exciting times to be involved in the pharmacovigilance arena. Companies, however, are struggling with the additional burden introduced by the new system and have suggested several improvements.

Enhanced EudraVigilance System Goes Live, EMA Updates Info For Users

After months of preparations, the European Medicines Agency’s improved pharmacovigilance database has gone live on schedule.

EMA Pilot To Help Companies ‘Ease In’ To New EudraVigilance System

The European Medicines Agency will use a phased approach to help companies comply with their obligation to monitor the revamped EU pharmacovigilance database and to report validated signals. Under a pilot to be launched on Feb. 22, 2018, companies will only have to monitor and report signals on drugs under additional monitoring.

Topics

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel